A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients With DSM-IV-TR Schizophrenia Followed by Open-Label Treatment With LY2140023.

Trial Profile

A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients With DSM-IV-TR Schizophrenia Followed by Open-Label Treatment With LY2140023.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2013

At a glance

  • Drugs Pomaglumetad methionil (Primary) ; Aripiprazole
  • Indications Schizophrenia
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 29 Aug 2012 Status changed from active, no longer recruiting to discontinued, according to an Eli Lilly media release.
    • 15 May 2012 Planned end date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 15 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top